Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jan 15;10:377. doi: 10.1038/s41598-019-57285-y

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Pathways mediating acute EMT are not required for the maintenance of chronic EMT or EMT memory. (A) E-cadherin expression following 48 hours of chemical inhibition of IL-1β-activated signaling pathways. (B) A549 cells were exposed to IL-1β for 48 hours following Fra-1 knockdown and examined for EMT markers. (C) A schematic mechanism of the IL-1β-induced acute EMT in A549 cells. (D) Evaluation of EMT markers with 48-hour inhibition of the MAPK (ERK and JNK) - AP-1 - SLUG axis in EMT memory. (E) Expression of SLUG, ZEB2, Fra-1, and JUN upon the JNK inhibition in EMT memory (-7d). (F) Expression of EMT markers with 14 days of Fra-1 knockdown (KD) following IL-1β withdrawal from the chronic treatment. (G) E-cadherin level and ERK signaling activity in A549 cells when being re-exposed to IL-1β after either 14 days of IL-1β withdrawal in EMT memory or 7 days of IL-1β exposure in acute EMT. (H) Evaluation of chemotherapy-induced apoptosis upon p65 knockdown in acute (48 hours), chronic EMT (24 days), and EMT memory (-7 days). U0126, ERK pathway inhibitor; SB203580, p38 inhibitor; LY294002, PI3K inhibitor; JNKi II, JNK inhibitor; BMS345541, IKK inhibitor; “U + J”, U0126 and JNKi II combination treatment. “-d/-h”, days/hours after IL-1β withdrawal; “p”, previously treated with IL-1β. Cis, cisplatin; Doxr, doxorubicin. All results are reported as mean ± SEM. ****P < 0.0001. See also Fig. S4.

HHS Vulnerability Disclosure